Published on 8 March 2024

A series of technology updates to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), held 6-9 March, in Florence.

New figures highlighting significant benefits of continuous glucose monitoring (CGM) use for people living with type 2 diabetes will be presented this week at ATTD.

In addition, reports are to be given on recent research demonstrating a direct association between CGM use and reduced mortality in people with type 1 and type 2 diabetes.

Last year Dexcom launched the G7 sensor, a real-time CGM technology, followed by the release of their latest sensor, Dexcom ONE+, built based on user and healthcare professional feedback and designed to be easy to use for anyone living with diabetes.

Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom, said: “Since last year’s ATTD, Dexcom has moved at an extraordinary pace. We launched G7 in 16 additional countries, released Dexcom ONE+ and are today announcing the phased launch of ‘Direct-to-watch’, that’s two best-in-class products and a feature designed to empower even more people living with diabetes. Globally, we have expanded access to Dexcom products by over 5 million people.”

CGM on an arm.

A recent study has highlighted the benefits of CGM with a reduction in mortality for people treating type 1 or type 2 diabetes with insulin.

Researchers believed these results showed that use of CGM could have broad-based benefits that extend beyond glucose lowering in patients with diabetes on insulin.

Another recent study by Dexcom has shown clinically meaningful reduction in HbA1c specifically for people managing their type 2 diabetes with a GLP1 and using a CGM sensor compared to groups not using CGM.

The research found that among people living with type 2 diabetes, the more regularly a CGM device was worn, the more time a user spent within their desired glucose range.

Dr Thomas Grace, MD, Head of Clinical Advocacy and Outcomes at Dexcom, said: ““The breadth of studies and outcomes showcased here at ATTD demonstrates the crucial role that Dexcom CGM can play in the treatment of type 2 diabetes.

“From demonstrating a clinically significant decrease in HbA1c to increasing time in range and generally improving well-being, the results speak for themselves. We also continue to see studies confirm that whilst GLP1s are an effective initial treatment for those living with type 2 diabetes the use of Dexcom CGM can strengthen their impact and provide an alternative for sustained long-term metabolic health improvement.”

For more information about these presentations and to register to virtually attend the conference, visit here 

I would like to make a regular donation of


I would like to make a single donation of

There are lots of ways to raise money to support
people living with all forms of diabetes.

Bake, Swim, Cycle, Fly ... Do It For DRWF!

Fundraise with us

Recent News